Eden Research plc (EDEN)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 2.450 |
|---|---|
| 52-week range | 1.900 – 5.000 |
| Return, 1 month / 3 months | +16.7% / −15.5% |
| Return, 1 year / 3 years | −2.0% / −47.9% |
| Trend | Below its 200-day average |
| RSI (14) | 67 |
| Volatility (1 year) | 53.3% |
| Worst drawdown (1 year) | -58.3% |
| Average daily value traded | 1.31M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eden Research is a British company that develops natural crop protection products for agriculture. It makes biopesticide formulations based on plant-derived compounds, sold under brand names for use on crops such as grapes and vegetables, and it also supplies encapsulation technology that helps deliver active ingredients. Its customers are growers, distributors and agricultural businesses seeking alternatives to conventional chemical treatments. The company is based in the United Kingdom and works with partners to bring its products to markets internationally.
Eden Research plc trades under the code EDEN on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eden Research plc (EDEN) trades on the London Exchange in UK. It last closed at GBX 2.450 on 23 October 2026.
Its price-based Market X-Ray is 23 out of 100 (a weak price profile), ranking 3,347 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 2.0% and over the last three months it fell 15.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 12 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.6% | ||
| From 52-week high | -49.0% | ||
| Momentum | 17 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -15.5% | ||
| 6-month return | -31.9% | ||
| 12-month return, skipping the last month | -16.0% | ||
| Stability (higher is calmer) | 19 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 53.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -58.3% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.31M GBX | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +16.7% |
| 3 months | −15.5% |
| 6 months | −31.9% |
| 1 year | −2.0% |
| 3 years | −47.9% |
| 5 years | −69.8% |
Signals
| 50-day / 200-day average | 2.267 / 3.047 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.308 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.